

Literaturübersicht suPAR

Notaufnahme

- Velissaris et al., 2020, Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group
- Schultz et al. 2018, Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III)
- Rasmussen et al., 2018, Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study
- R. Uusitalo-Seppälä et al., 2017, Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study

1

Allgemein

- Hartmann Rasmussen et al., 2016, Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study

Respiratorische Erkrankungen

- Rovina et al., 2020, Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
- Kyriazopoulou et al., 2020, Anakinra To Prevent Respiratory Failure In COVID-19
Hayek, 2015, suPAR in CKD

Nephrologie

- Azam et al., 2020, Soluble Urokinase Receptor (SuPAR) in COVID-19 – Related AKI
- Hayek et al., 2020, Soluble Urokinase Receptor and Acute Kidney Injury

Infektionskrankheiten

- Desmedt et al., 2017, The intriguing role of soluble urokinase receptor in inflammatory diseases

Kardiovaskuläre Erkrankungen

- R. Lyngbæk et al. ,2013, Soluble Urokinase Plasminogen Activator Receptor for Risk Prediction in Patients Admitted with Acute Chest Pain

Sie benötigen telefonische Beratung? +49 2234 98795 60

Per E-Mail: produktmanagement@bestbion.com

oder per Chat auf unsere Website:

www.bestbion.com/kontakt